Project Grant R01AI181316
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$787K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,350,312 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Los Angeles (UCLA) to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The project aims to create and optimize novel fluorescent trehalose probes that can detect live Mycobacterium tuberculosis and assess drug resistance, addressing critical limitations...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), seeks to optimize novel inhibitors of mycolic acid synthesis as TB drug candidates. The $237,288 award to the University of Central Florida will focus on hit-to-lead optimization and elucidation of structure-activity relationships, using whole cell potency and ADME/PK properties to drive compound prioritization....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $813,373 in funding to Rutgers, The State University of New Jersey to conduct research on developing new classes of pyrazinoic acid prodrugs against pyrazinamide-resistant Mycobacterium tuberculosis. The key goals of this 5-year research project are to characterize the diverse set of Mycobacterium tuberculosis amidases...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405.00 to Colorado State University and its subrecipient, the University of Tennessee Health Science Center, to develop new drug regimens for treating tuberculosis (TB), including both drug-sensitive and multidrug-resistant strains. The key objectives are to: 1) manufacture and characterize inhalable dry...
This federal Project Grant award of $1,635,882 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research into developing pro-apoptotic drug treatments for pulmonary tuberculosis (TB). The research aims to leverage cutting-edge imaging technologies and immunophenotyping approaches to gain mechanistic insights on how pro-apoptotic drugs can be used as host-directed therapies to shorten TB...
This $162,000 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The Washington University, the grant recipient, will leverage their mouse model of MTB infection to quantify pDC lung trafficking, identify the chemokine receptor required for pDC lung...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $265,650 to support research into developing novel medicinal chemistry strategies to overcome drug-resistant tuberculosis (TB). The research aims to (i) establish the structure-activity relationship and mechanism of action of modified rifabutin (RFB) analogs that have shown enhanced potency against...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $302,421 to Progenra Inc. to evaluate Parkin activators as potential treatments for tuberculosis (TB), including drug-resistant forms of the disease. The research aims to investigate the antimycobacterial efficacy of these small molecule compounds in cellular and animal models of TB, as well as study their mechanism of...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The award aims to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in TB control and reactivation, as well as characterize the cellular mechanisms of BMP pathway activation during TB...
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to improve the detection and study of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) Develop new imaging technologies capable of detecting single MTB bacteria in vitro and in vivo; 2) Use...